Skip to content
Safety information · Internal patient-safety page

Semaglutide safety summary

Semaglutide is a GLP-1 receptor agonist that works in the brain's appetite centres and slows stomach emptying, so you feel fuller for longer and eat less. It is prescribed for chronic weight management alongside a reduced-calorie diet and increased physical activity.

Semaglutide

What it's used for

  • Once-weekly self-injection in the thigh, abdomen or upper arm.
  • Dose is escalated gradually (0.25 mg → 0.5 → 1.0 → 1.7 → 2.4 mg) over 16 weeks to limit gastrointestinal side effects.
  • Combined with diet and physical activity, semaglutide is not a substitute for lifestyle change.

Most common side effects

  • Nausea, vomiting and diarrhoea.
  • Constipation, abdominal pain, bloating, reflux.
  • Headache and fatigue.
  • Hypoglycaemia (low blood sugar) when used alongside insulin or sulfonylureas, not a typical risk on semaglutide alone.
  • Injection-site reactions (redness, mild swelling).

Serious side effects: stop and seek care

  • Severe abdominal pain radiating to the back (possible pancreatitis): stop the medicine and seek urgent care.
  • Gallbladder problems: sudden right-upper abdominal pain, jaundice, fever.
  • Sudden vision changes in patients with type 2 diabetic retinopathy: see an ophthalmologist promptly.
  • Signs of severe dehydration from prolonged vomiting / diarrhoea: risk of acute kidney injury.
  • Severe allergic reaction (rash, swelling, breathlessness).

Who should not take it

  • Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2).
  • Pregnancy, planned pregnancy in the next 2 months, or breastfeeding.
  • History of pancreatitis or active pancreatic disease.
  • Type 1 diabetes or diabetic ketoacidosis: semaglutide is not approved here.
  • Severe gastroparesis or chronic severe gastrointestinal disease.

Interactions to flag

  • Insulin or sulfonylureas: risk of hypoglycaemia; the doctor may lower the dose of those.
  • Oral medicines with a narrow absorption window (e.g. levothyroxine, some oral contraceptives): semaglutide slows gastric emptying so timing may need adjusting.
  • Warfarin or other vitamin-K antagonists: INR monitoring may be tightened in the first weeks.
  • Alcohol: heavy use raises pancreatitis risk.

Message us in the app chat if you notice any of these

  • Severe or persistent vomiting, dehydration, or inability to eat for more than 48h.
  • New, severe abdominal pain that doesn't ease: A&E first.
  • Pregnancy or a positive pregnancy test: stop the medicine immediately.
  • A new medication or condition since your last consultation.
EMA: Wegovy product information

This page summarises information from the regulator-approved leaflet for reference only. It does not replace the full leaflet, linked on this page, it is not medical advice and it does not replace the assessment of an EU-licensed doctor. Your doctor will review your individual history, dose and interactions during your consultation.

Back to your consultation